Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-11-17
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving cetuximab together with combination chemotherapy may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with combination
chemotherapy works as first-line therapy in treating patients with metastatic colorectal
cancer.